8-K: Viatris Reports Mixed 2024 Results, Provides 2025 Guidance Amidst Challenges

Viatris announces its fourth quarter and full year 2024 financial results, meeting guidance for total revenues, adjusted EBITDA, and adjusted EPS, while exceeding free cash flow guidance, and provides its 2025 financial outlook, which includes the impact of the Indore facility warning letter and import alert.

Summary

• Viatris reported total revenues of $14.7 billion for 2024, with a U.S. GAAP net loss of $(634) million.
• Adjusted EBITDA was $4.7 billion, and adjusted EPS was $2.65 per share.
• The company generated $2.3 billion in U.S. GAAP net cash from operating activities and $2.0 billion in free cash flow, including ~$650 million of transaction-related costs.
• New product revenues reached $582 million in 2024.
• Viatris returned $825 million in capital to shareholders and repaid $3.7 billion of debt in 2024.
• The company expects six Phase 3 data readouts and important late-stage development milestones for innovative assets in 2025.
• 2025 financial guidance includes an expected negative impact from the Indore facility warning letter and import alert.
• Viatris is initiating an enterprise-wide initiative to review its global infrastructure and identify additional cost savings.
• Fourth quarter total net sales were $3.5 billion, up 1% on a divestiture-adjusted operational basis compared to fourth-quarter 2023 results.
• The company expects to deliver $450 million to $550 million in new product revenues in 2025.
• The company paid down approximately $1.4 billion in debt in the fourth quarter (approximately $3.7 billion for the year) and achieved its long-term gross leverage target, ending the year at 2.9x.
• The company currently estimates the negative impact on 2025 total revenues to be approximately $500 million and to 2025 adjusted EBITDA to be approximately $385 million due to the FDA warning letter and import alert from the U.S. Food and Drug Administration (FDA) in December 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company met some financial targets and is returning capital to shareholders, the negative impact of the FDA warning letter and import alert tempers the overall outlook.

Positives

• Viatris met its 2024 financial guidance for key metrics.
• The company exceeded its free cash flow guidance for 2024.
• Viatris generated significant revenue from new products.
• The company reduced its debt and returned capital to shareholders.
• Viatris is advancing its pipeline with several late-stage development milestones expected in 2025.
• The company achieved its long-term gross leverage target.

Negatives

• Viatris reported a U.S. GAAP net loss of $(634) million for 2024.
• The company faces a significant negative impact on 2025 revenues and adjusted EBITDA due to the FDA warning letter and import alert for its Indore facility.
• Total revenues declined ~(4)% for the year ended December 31, 2024.
• U.S. GAAP Net Cash Provided by Operating Activities declined (21)% for the year ended December 31, 2024.

Risks

• The FDA warning letter and import alert for the Indore facility pose a significant risk to 2025 financial performance.
• The company anticipates some impact in other markets, including to parts of its ARV business in Emerging Markets and to select generic products in Europe.
• The company's ability to successfully remediate the issues at the Indore facility and regain FDA approval is uncertain.
• The company's financial guidance excludes the impact of divestiture-related taxes and transaction costs, as well as any acquired IPR&D for unsigned deals, which could affect actual results.
• The company's future performance depends on the success of its pipeline and new product launches.

Future Outlook

Viatris expects total revenues between $13.5 billion and $14.0 billion, adjusted EBITDA between $3.9 billion and $4.2 billion, adjusted EPS between $2.12 and $2.26, and free cash flow between $1.8 billion and $2.2 billion for fiscal year 2025, excluding divestiture-related taxes and transaction costs.

Management Comments

• Scott A. Smith, CEO, stated that 2024 was a good year for Viatris with full year operational revenue growth of 2%, excluding divestitures, in line with guidance.
• Scott A. Smith, CEO, said that in 2025, the company is focused on driving strong commercial execution, advancing its pipeline, prioritizing capital return, executing its remediation plan for Indore, and beginning an enterprise-wide initiative to review its global infrastructure and identify additional cost savings.
• Doretta Mistras, CFO, stated that the company delivered strong cash flows, strengthened its balance sheet, and achieved its long-term gross leverage target in 2024.
• Doretta Mistras, CFO, said that the company's focus in the year ahead will include executing on its 2025 operating plan, identifying opportunities to grow its business and streamline its global infrastructure, and prioritizing capital return to shareholders.

Industry Context

Viatris operates in the global healthcare industry, facing competition from both generic and branded pharmaceutical companies; the company's focus on new product launches and pipeline development is consistent with industry trends aimed at driving growth and innovation; the FDA warning letter and import alert highlight the regulatory scrutiny and compliance challenges faced by pharmaceutical manufacturers.

Comparison to Industry Standards

• Viatris's adjusted EBITDA margin of approximately 31.8% ($4.7 billion/$14.7 billion) is comparable to other large generic and specialty pharmaceutical companies such as Teva Pharmaceutical Industries and Mylan (prior to its combination with Upjohn).
• The company's debt repayment of $3.7 billion reflects a commitment to deleveraging, a common strategy among pharmaceutical companies following major acquisitions or mergers.
• The planned share repurchases of $500 million to $650 million indicate a focus on returning capital to shareholders, a practice often seen in mature pharmaceutical companies with stable cash flows.
• The expected negative impact of $500 million on revenues due to the Indore facility issues is significant and could be compared to revenue losses experienced by other companies facing similar regulatory challenges, such as plant shutdowns or product recalls.

Stakeholder Impact

• Shareholders may be impacted by the share repurchase program and the company's financial performance.
• Employees at the Indore facility may be affected by the remediation efforts and potential changes in operations.
• Customers and patients may experience supply disruptions due to the import alert.
• The company is working closely with its customers to mitigate any possible supply disruptions and meet the needs of patients and will continue to work to ensure that the FDA is satisfied with the steps that have been taken to resolve all the points raised.

Next Steps

• Viatris will focus on executing its 2025 operating plan.
• The company will continue to advance its pipeline and pursue new product launches.
• Viatris will prioritize capital return to shareholders through share repurchases.
• The company will work to remediate the issues at the Indore facility and regain FDA approval.
• Viatris will begin an enterprise-wide initiative to review its global infrastructure and identify additional cost savings.
• The company anticipates requesting FDA to conduct a reinspection of the facility in a few months.

Key Dates